The painkillers market will reach $68.0 billion in 2013

Friday 30 August 2013, Amsterdam

A new report predicts that the world market for drugs to relieve pain will reach $68.0 billion for 2013. That revenue forecast appears in World Pain Relieving Drug Market 2013-2023, published in July 2013.
 
The study forecasts that the overall market for pain relieving drugs will grow steadily from 2013 to 2023. The world pain-treating drug market is a high-revenue industry with a high public and healthcare profile. Market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes.

Growth of the pain treatment market will continue to be stimulated by new drugs and reformulations of existing products from 2013 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. We believe that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and the market.

Rodrigo Gutierrez Gamboa, a pharmaceutical industry analyst said: “The pain relief market continues to be a dynamic, high-revenue market that can be profitable, even if it is challenging for participating companies. The world population is experiencing an increase in disease prevalence, as a result of an ageing world population and high, rising incidence of cancer, arthritis and diabetes. This will result in the pain drug market being driven towards revenue growth from 2013. Market expansion will continue to be dependent upon reformulations of existing drugs and launch of novel pain treatments, providing more-efficacious drugs, improved drug delivery, new dosing schedules and better-served patient populations.”

This report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. The study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:

• Narcotics
• Non-narcotics
• Neuropathic pain relievers
• Treatments for migraines
• Treatments for arthritis.

The investigation predicts revenues of 29 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson and Johnson, Bristol-Myers Squibb and other pharmaceutical companies.

That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5), India, China, Brazil, Russia and Turkey.